AZ
Biotech

AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre

AstraZeneca is paying $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s COPD drug Ohtuvayre.
Nick Paul Taylor Jul 8, 2026 5:00am
pause halt pause button

FDA halts release of new drug rejection letters

Jul 8, 2026 1:33pm
ArticlePrimaryImagejpg

Can We Outrun Cancer's Evolution? Why We Need a New Approach

Brought to you by BrYet US, Inc.
Law Legal System Justice Crime concept Mallet Gavel Hammer and Scales on tabl

Prime wins gene editing patent fight with Beam

Jul 8, 2026 11:07am
Duchenne muscular dystrophy DMD

Satellos’ ‘intriguing’ DMD data raise hopes ahead of key readout

Jul 8, 2026 9:48am
Deal

Scipher picks up Chemomab’s RA drug, Nasdaq listing in merger

Jul 8, 2026 9:26am
More News
Fierce Healthcare

Leo Cancer Care secures $65M for upright radiotherapy

Jul 8, 2026 8:45am

Fierce Biotech Layoff Tracker 2026: BioCryst, Biogen, & more

Jul 8, 2026 7:30am

Caidya and Simbec-Orion unite in global CRO combo

Jul 7, 2026 3:59pm

MeiraGTx scores $400M to boost commercialization push

Jul 7, 2026 2:33pm